Skip to main content
Free trial

Ask AI to review this stock

Copy the prompt to get recent events, historical reactions, and a short research brief.

Tell your AI:

Help me set up FinLab and analyze 4905 台聯電. Please read: https://finlab.finance/en/setup?stock=4905

4905

台聯電 Biotech & Healthcare As of 2026-06-17 Updated daily after market close

quality needs a look, fair valuation, no active signal today.

This page refreshes daily after the close. Add 台聯電 to your watchlist to track signal changes on your next visit.
Valuation 69Quality 40Growth 32Momentum 30Chips 29

Is 台聯電 a buy? Fundamentals and valuation first

  • Weak profitability.Operating margin is in the 29th market percentile. Latest quarterly ROE ≈ 1.9%.

  • Valuation is neutral.PE is in the 36th market percentile; within its own history, PE is around the 53th percentile.

  • Foreign investors are net selling.Foreign 20-day net flow ≈ -1.2% of volume (net sell).

Chip flow

Bullish +0.31
BearishNeutralBullish

Single-sided accumulation, concentration rising — bullish

  • Single-sided accumulation, concentration rising — bullish
  • 富邦-台北 holds 91 lots
  • sellers have 46 lots left, ~80 sessions to clear

Window from 2026-01-17 · Price +18% · branches to 2026-06-17· TDCC to 2026-06-12

  • Largest holder 富邦-台北 has accumulated 91 lots since the start (sold 0%), still adding.
  • Main distributor 元大證券 peaked at 40 lots, has sold 88%, 5 left, paused recently.
  • TDCC big holders (absolute) >1000-lot holders +0.18pp, mid holders +0, retail +0.03pp — concentration shifting upward.
  • Foreign hedge-desk net short Net short -28 lots (inferred from branch profile, mostly hedging — not necessarily bearish, not case-confirmed).
Branch inventory reconstruction
Accumulating holders Branches that accumulated shares during the window and still hold positive inventory; they are the absorbing side.
Distributing sellers Branches that built inventory earlier and have been selling it down; the remaining number estimates what has not cleared.
Net-short desks Trading-desk branches with negative inventory or net selling, often hedge, offsetting, or short-term flow. It is not automatically a bearish view.
Accumulating
富邦-台北富邦-仁愛群益金鼎-北高雄統一-金門合庫-桃園元大-北投
Distributing
元大證券群益金鼎-市府兆豐-新竹華南永昌-長虹台灣摩根士丹利群益金鼎-館前
Desks
own scale
台新-建北統一群益金鼎大昌-樹林
Price Accumulating & Distributing share one scale (comparable); Desks is independent. Zero is the baseline
Branch details Unit: lots

Accumulating

  • 富邦-台北 +91
    sold 0%· still adding
  • 富邦-仁愛 +62
    sold 23%
  • 群益金鼎-北高雄 +27
    sold 0%· still adding
  • 統一-金門 +24
    sold 0%
  • 合庫-桃園 +16
    sold 0%
  • 元大-北投 +16
    sold 0%· still adding

Distributing

  • 元大證券 5 left
    sold 88%· paused recently
  • 群益金鼎-市府 24 left
    sold 25%· ~80 sessions to clear
  • 兆豐-新竹 2 left
    sold 85%· paused recently
  • 華南永昌-長虹 7 left
    sold 42%· paused recently
  • 台灣摩根士丹利 7 left
    sold 36%· ~35 sessions to clear
  • 群益金鼎-館前 2 left
    sold 82%· paused recently

Desks

  • 台新-建北 -91
    unclassified
  • 統一 -74
    unclassified
  • 群益金鼎 -73
    unclassified
  • 大昌-樹林 -49
    unclassified
Still selling 46 lots ~80 sessions to bottom at most
Recent buy/sell force +103 absorbed / -18 sold buyers slightly ahead
Hedge-desk net short -1 lots potential cover-buying, not selling pressure
TDCC big holders · absolute-holding cross-check
>1000-lot holder share Retail (<400 lots) share Price (right axis)

Mixed direction: big-holder and retail changes are not aligned.

Describes chip flow, not investment advice. Branch data discloses only high-volume branches with ~1-day lag; TDCC is weekly. Inventory is a relative reconstruction from the window start, not absolute holdings.

Historical evidence

Valuation regime and subsequent returns

Each day's PE is converted to its own-history percentile (as of that day), then we look at adjusted-close returns over the next 240 trading days by valuation regime.

PE percentile bandSample days240-day avg returnMedianWin rateAvg excess (vs index)
0-20 545+16.9% +4.2% 52.3% -7.3%
20-40 129+21.6% +1.6% 57.4% +6%
40-60 You are here221+6.8% +2% 56.6% -15.7%
60-80 680+9% -1.9% 47.4% -27.8%
80-100 443+38.4% +37.5% 95% +33.7%

Percentiles use an expanding own-history window (no look-ahead); forward return is 240 trading days on adjusted close. Sample days overlap; distribution is indicative only.

Current PE ≈ 17.32, at the 53.2th percentile of its own history (40-60 band).

Valuation × momentum historical grid

Every day in its own history is bucketed by valuation tercile (own-history PE) and 60-day momentum sign into six cells; we show adjusted-close returns over the next 120 trading days per cell.

Valuation
Momentum
Cheap (own-history bottom 1/3)
Mid
Expensive (own-history top 1/3)
60-day momentum up
+7.5%
Win rate 46.2% Excess +3.4%
279d
+8.2%
Win rate 60.7% Excess -5.5%
326d
+11.5%
Win rate 66.1% Excess +0.4%
496d
60-day momentum down
+10.5%
Win rate 49.4% Excess +5%
308d
Now
+3.6%
Win rate 33.3% Excess -2.7%
267d
+13.2%
Win rate 65.9% Excess -15.9%
410d

Currently in “Mid × 60-day momentum down”: across 267 historical days, 120-day forward avg gained 3.6%, win rate 33.3%, lagged the market by 2.7%.

Days = trading days in this bucket; returns use adjusted prices, ex-costs. 60-day momentum: direction of this stock's price over the past 60 trading days.

Signals not active (historical stats for reference)

These are not occurring now; historical samples shown for comparison.

252-day price high (breakout)

Pending

Adjusted close makes a new 252-day high; repeats within 20 days counted once.

24 times historically; 60-day forward avg +2.83%, win rate 45.8%, beating the market by -0.54 pts on average.

Monthly revenue YoY ≥ 20% (from filing deadline)

Pending

Monthly revenue YoY ≥ 20%; event date is the first trading day after the filing deadline (no look-ahead).

95 times historically; 60-day forward avg +4.22%, win rate 56.6%, beating the market by -0.73 pts on average.

Foreign net buying for 5 straight days

Pending

Foreign net flow (ex-dealer) positive for 5 straight days; event on day 5; repeats within 20 days counted once.

15 times historically; 60-day forward avg +2.87%, win rate 40%, beating the market by +1.63 pts on average.

What does 台聯電 do? Company profile

生技醫療業;公司歷史核心亦屬通信網路設備,近年營收主體轉向醫療包材與特用化學 櫃買中心上櫃

Overview

4905 對應台聯電訊股份有限公司,英文名 TAINET COMMUNICATION SYSTEM CORP.,為上櫃普通股。公司成立於 1990/08/03,公開發行日 1998/07/22,上櫃日 2001/12/07,總部位於台北市內湖區瑞光路108號3樓,工廠位於台北市內湖區內湖路一段91巷23弄6號4樓。董事長為華盛國際投資股份有限公司,代表人張志成;總經理兼發言人為黃仲康。實收資本額約新台幣292,600,440元,已發行普通股29,260,044股,每股面額10元,無特別股。依公司 2025 年年報摘要,2025 年底集團員工約180人;依 2024 年年報,2024 年底員工162人,2025/04/15為165人。2025 年年報摘要顯示 2025 年合併營收726,755千元,較2024年592,991千元增加23%,稅後淨利94,666千元,歸屬母公司業主淨利80,685千元,EPS 2.76元,每股淨值98.24元。2024/04/15主要股東包括富鼎科技顧問股份有限公司13.86%、華盛國際投資股份有限公司11.71%、台晟國際投資股份有限公司7.38%、張齊學4.99%、渣打託管英瑞吉基金投資專戶4.89%、林珮如4.85%、張淯銓4.72%、張為瑄4.66%、渣打託管寶捷基金公司投資專戶4.50%、張志成4.29%。轉投資方面,公開資料列示欣德芮股份有限公司持股61.36%、達亞股份有限公司持股23.63%、福億通訊與聯創投資等子公司,顯示公司除營運事業外,也具有長期投資平台色彩。

Business

公司早期主業為自有品牌 TAINET 通信設備,近年透過併購與轉投資跨入醫療包材與液態矽橡膠特用化學。依 2025 年度營收組合摘要,醫療器材/醫療包材約75%、特用化學約16%、窄頻設備約1%、寬頻設備約7%、租賃收入約1%;2024 年度則為醫療器材75%、特用化學14%、窄頻設備4%、寬頻設備6%、租賃收入1%。通信產品包括專線式類比數據機、VoIP網路語音閘道器、智慧照護主機與系統、xDSL高速數位用戶迴路接取設備、光纖多工器、GEPON/GPON OLT/ONU/ONT、乙太網路終端設備、4G/5G與Wi-Fi無線整合設備、Auto Provision System自動供裝系統等,主要銷售給電信商、ISP、企業、金融與政府機構,並透過代理商或經銷商銷售。醫療包材事業主要透過欣德芮等子公司提供醫療器械滅菌袋、藥廠無菌轉運袋、醫院/診所/牙科滅菌袋、一次性滅菌包材、客製化醫療等級包裝材料與整體包裝解決方案,客戶包括醫院診所、藥廠、保健產品、醫療器材與工業設備廠。特用化學事業聚焦 LSR 液態矽橡膠,包括符合 ISO 10993 的醫療級液體矽橡膠、車用光學級液體矽橡膠、低溫快速硫化液體矽橡膠、選擇性接著液體矽橡膠,應用於日用品、3C電子、家電、音響、汽車、母嬰用品、工業、軍工、醫療與 VR/AR 等領域。2024 年銷售區域為台灣29%、亞洲55%、歐洲9%、其他7%;2025 年合併營收仍以醫療包材為主體,顯示公司商業模式已由單純網通設備供應商轉為醫療包材、特用材料、利基網通與投資收益並行。

Outlook 2025–2028

2025 至 2028 年主要成長動能有三條線。第一,醫療包材:全球高齡化、醫療器材與製藥需求成長,使滅菌包材需求具中期支撐;子公司欣德芮規劃於宜蘭科學園區設廠,官方與公司資料均指向醫療器械滅菌袋、藥廠無菌轉運袋等產品,2025 年公告租地委建廠房工程總價2.688億元,2024 年報則稱新廠初期產能可大幅滿足市場需求、製造面積可擴大至現有面積一倍以上、預計2027年投入生產,因此 2027 至 2028 年若量產順利,可能成為營收擴張關鍵。第二,特用化學/LSR:公司規劃台灣研發中心並保留核心技術,產品方向包含植入體內醫療級液體矽橡膠、耐化學性液體矽橡膠、車用光學級材料與低溫快速硫化材料;台灣 LSR 多仰賴進口,公司若能以本地化技術支援、交期與客製化切入高端客戶,有機會替代部分進口材料。第三,利基網通:5G、IoT、工業級行動路由、VoIP、智慧照護與自動供裝管理系統仍是公司技術延伸方向,但相較醫療包材與特用化學,營收占比已低,未來較可能扮演利基市場與系統整合角色。主要風險包括:醫療包材新廠建設與認證進度、量產良率及客戶導入不如預期;美國關稅與國際貿易政策不確定;醫療包材土地與人力成本高;LSR 原料價格波動、低階有機矽市場削價競爭、客戶更換材料的驗證成本與信任門檻;網通產品成熟化導致新競爭者加入與毛利率下滑;公司獲利仍受長期投資部位評價與投資收益波動影響。2026 至 2028 年財務預測未見公司正式揭露,因此對未來數字不作推估。

Supply Chain

Upstream
  • 印刷電路板、主動元件、Power IC、被動元件、晶片組供應商 通信設備上游原物料與零組件;年報僅揭露類別,未揭露具名供應商,故不填台股代號。
  • 特用包材、膜料、紙材、膠與醫療包裝材料供應商 醫療包材上游原料;公司稱採用特殊醫療包裝材質且具原料廠認證加工資格,但主要供應商以 AA、BB、CC 等代號揭露,未公開具名。
  • 有機矽與液態矽橡膠原料供應商 特用化學上游;年報稱已有穩定合作關係,但未揭露具名供應商。
  • 杜邦 欣德芮相關公開資料稱其為杜邦公司在台灣的唯一授權加工廠;杜邦為美國上市/海外企業,非台股掛牌。
  • 豐譽營造股份有限公司 2025 年台聯電代子公司欣德芮公告宜蘭新廠租地委建工程契約相對人,未確認為台股上市櫃公司。
Downstream
  • 民營電信商、ISP、ITSP、企業用戶、金融機構、政府機構與代理商 通信設備下游客戶類型;年報揭露類別而非具名客戶。
  • 醫院診所、藥廠、保健產品、醫療器械與工業設備廠 醫療包材下游客戶類型,採醫療等級認證包裝材料;具名客戶未公開。
  • 3C電子、車用、醫療、民生消費、工業、軍工、VR/AR 成型廠與終端客戶 LSR 液態矽橡膠下游應用與成型廠客群;具名客戶未公開。
  • 達亞 6762 台聯電持有達亞股份有限公司股權並為其董事;達亞為台灣上櫃生技醫療公司,屬投資與醫療產業布局關係,非年報揭露的直接銷貨客戶。

Competitors

  • 合勤控 3704 Zyxel 為年報列示之 xDSL、VoIP、PON 等產品競爭品牌;合勤控為台股上市櫃相關掛牌公司。
  • 新漢 8234 Nexcom 為年報列示高速數位用戶迴路接取設備競爭廠商;新漢為台股上櫃公司。
  • 居易 6216 DrayTek 為年報列示 VoIP 網路語音閘道器競爭廠商;居易為台股上櫃公司。
  • 普萊德 6263 PLANET 為年報列示乙太網路傳輸與行動無線網路路由設備競爭廠商;普萊德為台股上櫃公司。
  • 研華 2395 Advantech 為年報列示乙太網路傳輸、智慧家庭/智慧照護整合設備等競爭廠商;研華為台股上市公司。
  • 盛達 3027 Billion 為年報列示乙太網路傳輸與行動無線路由設備競爭廠商;盛達為台股上市櫃公司。
  • 明泰 3380 Alphanetwork 為年報列示被動光纖網路傳輸設備競爭廠商;明泰為台股上市公司。
  • 華碩 2357 ASUS 為年報列示智慧家庭及智慧照護整合設備競爭廠商;華碩為台股上市公司。
  • 大同 2371 TATUNG 為年報列示智慧家庭及智慧照護整合設備競爭廠商;大同為台股上市公司。
  • 凌群 2453 Syscom 為年報列示智慧家庭及智慧照護整合設備競爭廠商;凌群為台股上市公司。
  • Cisco 年報列示之 VoIP 競爭廠商,美國上市公司,非台股掛牌。
  • Huawei 年報列示之 VoIP 與 PON 競爭廠商,未上市且非台股掛牌。
  • Dow 年報列示全球領先 LSR 品牌廠,美國上市公司,非台股掛牌。
  • Momentive 年報列示全球 LSR 競爭品牌,非台股掛牌。
  • Wacker 年報列示全球 LSR 競爭品牌,德國上市公司,非台股掛牌。
  • Shin-Etsu Chemical 年報列示全球 LSR 競爭品牌,日本上市公司,非台股掛牌。
  • Elkem 年報列示透過併購急起直追之有機矽/LSR 競爭者,海外公司,非台股掛牌。
Sources(13)

This company profile is compiled from public sources (annual reports, filings, news and analyst reports), not finlab backtest data; the 2025–2028 outlook contains forward-looking estimates and is for reference only.

Method and limitations

  • All returns use adjusted close (etl:adj_close), already adjusted for dividends and splits.
  • Excess return is measured against the TAIEX total-return index (dividends included).
  • Valuation regime and percentile stats use an expanding own-history window (no future data).
  • Revenue-signal event dates align to the first trading day after the filing deadline, avoiding look-ahead.
  • Event samples may overlap in time; stats describe historical distribution only and are less reliable when samples are few.

This page is historical statistics for educational purposes and is not investment advice. Investing involves risk; past performance does not indicate future results. Assess and bear the risk yourself before trading.